Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 


FORM 8-K

 


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 2, 2007

 


PHARMASSET, INC.

(Exact Name of Registrant as Specified in its Charter)

 


 

Delaware   001-33428   98-0406340

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

303-A College Road East

Princeton, NJ

  08540
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (609) 613-4100

 

(Former Name or Former Address, if Changed Since Last Report.)

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) On November 2, 2007, Alexandra Goll, PhD voluntarily resigned from the board of directors of Pharmasset, Inc. effective immediately. Dr. Goll was a member of the Audit committee of the board of directors.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PHARMASSET, INC.
Date: November 2, 2007   By:  

/s/ KURT LEUTZINGER

  Name:   Kurt Leutzinger
  Title:   Executive Vice President and Chief Financial Officer